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Abstract
Background: Obesity is associated with chronic low-grade inflammation and hyperinsulinism that may influence
the progression of endothelial dysfunction and atherosclerosis already in childhood.
Methods: To study changes in metabolic profile and markers of inflammation and endothelial activation in
children with primary severe obesity after weight loss we involved 14 obese children (Ob) that underwent a lifestyle
intervention and 18 normal weighted subjects (C). In Ob, anthropometric data were assessed both at baseline and
after intervention together with oral glucose tolerance test and fasting evaluation of cholesterol assessment,
interleukin-6, endogenous secretory receptor of advanced glycation end products and endothelin levels.
Results: At baseline, serum IL-6 concentrations resulted significantly higher in Ob respect to C (12.96 ± 8.87 vs.
4.88 ± 1.19 pg/ml, p<0.05). After weight loss, Ob significantly improved glucose metabolism and lipid assessment
and they showed a significant reduction of all markers of inflammation and endothelial activation. In all subjects
studied, BMI-SDS correlated positively with interleukin-6 (r 0.45, p<0.05).
Conclusion: Our results demonstrated higher concentrations of inflammatory markers in obese children
compared to healthy subjects. Nevertheless, an early lifestyle intervention could improve the levels of these
molecules together with cholesterol and glucose metabolism and may reverse the development of premature
endothelial dysfunction in obese children.
Keywords: Children; Inflammation markers; Life style intervention;
Obesity; Weight loss
Introduction
Obesity is a major public health problem in industrialized countries
[1] A recent survey demonstrates that 21-24% of American children
and adolescents are overweight and 16-18% obese [2]. A similar
epidemic condition is undergoing in Italy, where overweight and
obesity affect nearly 40% of children in Central and Southern regions
[3]. Childhood and adolescent obesity is predictive of adult obesity, as
previously documented [4]. Overweight and obesity are associated
with hyperinsulinism and insulin resistance with an increased
incidence of dyslipidemia, type 2-diabetes and cardiovascular disease
already in childhood and adolescence; in particular, it has been shown
that severe childhood obesity is independently associated with
endothelial dysfunction and arterial wall thickening [5]. These
pathological conditions can persist in adulthood regardless of the
maintaining of excessive weight. Recent studies show that obesity is a
status of chronic inflammation characterized by the production of
cytokines by adipose cells [6]. It has been shown that adipose tissue
cells (adipocytes and macrophages) secrete a cascade of pro-
inflammatory cytokines, including interleukin-6 (IL-6), Tumor
Necrosis Factor-α (TNF-α), interleukin-1 (IL-1) and interleukin 10
(IL-10), as well as reagents oxygen and endothelial adhesion molecules
with a paracrine and systemic effect. This up-regulation of endothelial
adhesion molecules plays a basic role during the earliest phases of
atherogenesis and it causes dysfunction and activation of endothelial
cells, then promoting abnormal adhesion of leukocytes and platelets
and forming the basis of atherosclerotic plaque [7,8]. This low-grade of
persistent inflammation, associated with hyperinsulinemia may
influence the progression of endothelial dysfunction and it could be
responsible for the beginning of early obesity-associated
atherosclerosis in childhood Thus, obesity per se could promote
atherosclerotic plaque formation since the earliest ages and it could be
considered a strong predictor of coronary heart disease later in life [9].
The primary objective of the pediatrician must be to develop effective
strategies to early identify and treat diseases related to obesity in
children [10].
The aim of the present prospective and longitudinal study was to
investigate the changes of endothelial adhesion molecules and




The study included Italian children and adolescents with severe
obesity and normal weight subjects, matched according to age, gender
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and pubertal stage, attending the Pediatric Metabolic Disorders Clinics
of the University of Aquila and of the University of Modena and
Reggio Emilia, Italy, recruited between January and September 2015.
Exclusion criteria consisted of concomitant endocrinological
diseases and use of medications affecting insulin sensitivity or glucose/
lipid metabolism.
Obese children underwent to a 1-year long lifestyle intervention: a
gradual change in eating habits was proposed to the whole family
(appropriate balance of nutrients and correct distribution of meals in 5
times of the day, avoiding snacks, and restoring importance of
breakfast) and sedentary lifestyles were reduced increasing physical
activity. The food portions were estimated through simple benchmarks
in daily habits.
In Ob group, anthropometric data, biochemical parameters, serum
concentration of IL-6, endothelin 1(ET-1) and endogenous secretory
receptor of advanced glycation end products (esRAGE) were
determined both at baseline (time 0) and after intervention (time 1).
Written informed consent for data collection was obtained from all
subjects and parents at the moment of recruitment in the study and
before the first data collection. The approval of the local Ethics
Committees was obtained.
Body composition and definition of obesity
All patients underwent a complete clinical history and
anthropometric measurements that were performed by well-trained
examiners according to the Anthropometric Standardization Reference
Manual. Height was measured to the nearest 0.1 cm using a wall-
mounted stadiometer (Harpenden, Crymych; UK). Body weight was
measured to the nearest 0.1 kg and body mass index (BMI) was
calculated as weight in kg/height in meters squared and expressed as z-
score with respect to chronological age using national growth charts
(Cacciari 2006). Obesity was defined as BMI higher than the 95th
percentile for age and sex, severe obesity when BMI was higher 99th
percentile, whereas normal weight was defined as a BMI lower than the
85th percentile.
Laboratory measurements
Fasting lipid profile [total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and
triglycerides (TG)] was evaluated using the commercially available kits
for enzymatic test (Roche Diagnostics, Mannheim, Germany) which
has international consensus values for plasma lipids, ensuring that
magnitude of the potential difference is acceptable at 10%. The
sensitivity of the TC, HDL-C, and LDL-C assay was 3 mg/ml. Intra and
inter assay coefficients of variations (CVs) were less than 0.8% and
1.7%, respectively, for all examinations. The sensitivity of the TG assay
was 4 mg/ml, while intra- and inter assay CVs were 1.5% and 1.8%,
respectively.
Oral glucose tolerance test (OGTT) was performed at baseline and
at the end after the beginning of the lifestyle intervention. The glucose
load for OGTT was 1.75 g/Kg (maximum administered dose 75 g). The
categorization of glucose tolerance status was made using the World
Health Organization criteria.
Blood samples to measure inflammatory markers were obtained
after a 12-h fasting period and centrifuged at 3000 g at 4°C for 10 min
to obtain serum. Samples were frozen at −80°C until assayed.
ELISA (enzyme-linked immunosorbent assay) method was used to
detect esRAGE (esRAGE ELISA Kit; B-Bridge International Inc., CA,
USA) serum levels. The esRAGE concentrations were measured
according to user manual and they were determined by interpolation
of the regression curve formula. The sensitivity of the assay was 0.05
ng/ml. No significant cross-reactivity or interference was observed in
these assays.
ET-1 serum concentrations were assayed using enzymatic kits
(TiterZyme®, Assay Designs Inc., MI, USA). The sensitivity of the assay
was 0.14 pg/ml. The intra assay CVs according to low, medium and
high concentrations of ET-1 were 8.5%, 5.8%, and 4.6%, respectively;
the inter assay CVs were 8.1%, 4.7%, and 3.1%, respectively.
IL-6 levels were determined by ELISA method using the Quantikine
kit (R&D System), the minimum detectable concentration was 0.10
pg/ml and the interassay CV was 7.0%.
Statistical analysis
All normally distributed variables (BMI, z-score BMI) were
expressed as mean ± SD. Data not normally distributed (TC, LDL-C,
TG, HDL-C, glycaemia and insulin at baseline and at 120 minutes after
OGTT, ET-1, IL-6, esRAGE) were log-transformed to approximate
normality and expressed as mean ± SD. Between group comparison of
anthropometric and biochemical data at time 0 were evaluated using
Mann-Whitney’s U-test. In Ob group, longitudinal changes of
anthropometric, biochemical, and inflammatory data were analyzed
using the Wilcoxon matched pair test. Spearman’s correlation analysis
was performed to assess the relationship between variables. The
association between potential predictors and longitudinal changes of
inflammatory markers was evaluated using the multiple linear
regression model including Δ ET-1, Δ IL-6, and Δ esRAGE as
dependent variables and anthropometric and biochemical data (with
an association with the dependent variable in univariate analysis at
15% significance level) as independent variables. Statistical significance




Age (years) 11.00 ± 0.10 10.40 ± 1.64
BMI (kg/m2) 28.53 ± 3.38 17.14 ± 2.34*
BMI SDS 2.90 ± 0.44 0.17 ± 0.91*
ET1 (pg/ml) 9.35 ± 4.57 6.13 ± 4.25
IL-6 (pg/ml) 12.96 ± 8.87 4.88 ± 1.19*
esRAGE (ng/ml) 0.37 ± 0.11 0.51 ± 0.28
Legend: *p<0.05 between groups
Table 1: Baseline features in study population.
Thirty two subjects entered the study: 14 children and adolescents
with severe obesity [group Ob, 6 boys and 8 girls, aged 11.0 ± 0.10
years, body mass index (BMI)>99th percentile) and 18 normal weight
subjects (group C, 9 boys and 9 girls, aged 10.4 ± 3.64 years, BMI <85th
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percentile); baseline data of group Ob and group C patients are
outlined in Table 1.
At time 0 IL-6 levels were significantly higher in Ob group than in C
group (12.96 ± 8.87 vs. 4.88 ± 1.19 pg/ml, respectively; p=0.002; Table
1) while ET-1 and esRAGE concentrations were not significantly
different.
Longitudinal data
All patients of Ob group were longitudinally evaluated at the end of
the study.
Weight loss (Figure 1a) and the improvement of both glycaemic
control and lipid profile were longitudinally demonstrated in our Ob
group (Table 2). Specifically, the lifestyle intervention treatment from
time 0 to time 1 significantly decreased z-score BMI (2.90 ± 0.44 vs.
2.22 ± 0.52 SDS, respectively; p<0.001), TG levels (90.92 ± 38.50 vs.
65.71 ± 17.72 mg/dl, respectively; p<0.001), both glycaemia
(103.61±7.80 vs. 86.91±15.20 mg/dl, respectively; p=0.005) and insulin
(84.77 ± 39.56 vs. 55.21 ± 24.50 microIU/ml, respectively; p=0.01,) at
120 minutes after OGTT. HDL-C values increased significantly from
40.78 ± 5.88 to 50.14 ± 15.67 mg/dl (p=0.04). The other parameters of
lipid profile did not change despite intervention (Table 2).
Time 0 Time 1
BMI (kg/m2) 28.53 ± 3.38 25.65 ± 3.68°
BMI SDS 2.90 ± 0.44 2.22 ± 0.52°
CT (mg/dl) 160.92 ± 21.83 160.21 ± 19.02
LDL-C (mg/dl) 101.57 ± 23.45 99.71 ± 20.99
HDL-C (mg/dl) 40.78 ± 5.88 50.14 ± 15.67°
TG (mg/dl) 90.92 ± 38.50 65.71 ± 17.72°
OGTT test:
Baseline glycaemia (mg/dl) 77.28 ± 8.52 75.85 ± 7.32
120 min glycaemia (mg/dl) 103. 61 ± 14.44 86.91 ± 15.20°
Baseline insulin (uIU/ml) 17.92 ± 7.80 15.64 ± 7.81
120 min insulin (uIU/ml) 84.77 ± 39.56 55.21 ± 24.50°
Legend: °p < 0.05 vs. Time 0
Table 2: Longitudinal analysis of anthropometric and biochemical data
in obese patients.
Together with the previously described metabolic changes a
significant decrease of inflammatory markers levels was found (Table
3, Figures 1b-1d). In particular, from time 0 to time 1, ET-1 (9.35 ±
4.57 vs. 5.46 ± 4.41 pg/ml; p<0.001) and IL-6 (12.96 ± 8.87 vs. 5.60 ±
4.91 pg/ml; p<0.001) concentrations were significantly decreased;
moreover, a significant increase of esRAGE levels (0.37 ± 0.11 vs. 0.47
± 0.17 ng/ml, p<0.0001) was demonstrated (Table 3). Figure 1 depicts
the Δ of inflammatory markers (b, c, and d) along follow-up.
At baseline, in the total population, we found a significant and
positive correlation between IL-6 concentrations and z-score BMI
(r=0.458, p<0.05).
Time 0 Time 1
ET1 (pg/ml) 9.35 ± 4.57 5.46 ± 4.41°
IL-6 (pg/ml) 12.96 ± 8.87 5.60 ± 4.91°
esRAGE (ng/ml) 0.37 ± 0.11 0.47 ± 0.17°
Legend: °p < 0.05 vs. Time 0
Table 3: Longitudinal analysis of inflammatory markers in obese
patients.
Figure 1: Metabolic changes.
No anthropometric and biochemical variable was identified as
significant predictive factor for reduction of ET-1, IL-6 and increase of
esRAGE in group Ob.
Discussion
In our study lifestyle modifications, including combined diet and
moderate regular physical exercise, significantly reduced BMI and z-
score BMI and improved insulin sensitivity and lipids profiles.
Moreover, together with these metabolic changes, in our Ob group the
serum levels of IL-6, ET-1, and esRAGE significantly improved along
follow-up.
It has been already shown that IL-6 concentration, normally
expressed in white adipose tissue and in peripheral blood mononuclear
cells, increases progressively with adiposity [11] and, along with other
pro-inflammatory cytokines, may substantially influence obesity
development and metabolic disorders such as type 2 diabetes. IL-6
plays a significant role in energetic homeostasis and lipid-carbohydrate
metabolism and it is an upstream inflammatory cytokine that plays a
central role in propagating the downstream inflammatory pathway
responsible for atherosclerosis. In our study, the decrease of IL-6 levels
after weight loss indicates that its secretion by the adipocyte can be
modulated by lifestyle changes.
The most potent vasoconstrictor peptide synthesized by the
endothelial cells is ET-1 and it appears to play a central role in the
pathophysiology of the vasomotor abnormalities associated with
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endothelial dysfunction; moreover, it is involved in the progress of the
atherosclerotic plaque [12]. It mediates host responses, including
endothelial dysfunction, vasomotor contraction, leukocyte and platelet
activation, and cellular proliferation. An increased activity of the ET-1
system probably may contribute to the abnormal vascular homeostasis
in obese patients. Endothelial injury is the main stimulus for ET-1
secretion. Children and adolescents with obesity, hypertension or
diabetes have higher ET-1 plasma concentrations than healthy
subjects, and its level correlates with BMI, lipid parameters and systolic
blood pressure [13]. Our data confirm published data but it is
important to underlie how in our Ob subjects ET-1 levels significantly
decreased after weight loss due to the only lifestyle intervention.
During these last years, both the soluble secretory receptors for
advanced glycation end products (sRAGE) and the esRAGE were
demonstrated to be involved in the pathogenesis of cardiovascular
diseases [14]. sRAGE is a multi-ligand cell-surface protein, belonging
to the immunoglobulin superfamily. RAGE interacts with other non-
glycated peptide ligands, including S-100/calgranulin, amphoterin,
amyloid fibrils and a leukocyte integrin, macrophage-1 antigen
(Mac-1). Ligand engagement of RAGE leads to prolonged
inflammation, and is also profoundly associated with macrovascular
complications in diabetes due to the expression of pro-inflammatory
mediators such as monocyte chemoattractant protein 1 (MCP-1) and
vascular cell adhesion molecule-1 (VCAM-1). Recently, numerous
truncated forms of RAGE have been described; they are spliced
variants of RAGE, which carry all of the extracellular domains but are
lacking of the trans-membrane and intracytoplasmic domains. They
bind ligands including advanced glycation end products (AGEs) and
can antagonize RAGE signaling in vitro and in vivo. A C-terminally
truncated soluble form of RAGE has received much attention; it is now
known to be present in human circulation and is named esRAGE.
esRAGE neutralizes the effects of AGEs on endothelial cells in culture.
Thus, the decoy function of esRAGE may involve a feedback
mechanism by which esRAGE prevents the activation of RAGE
signaling. It has also been suggested that some esRAGE isoforms that
could act as decoy receptors, may be cleaved proteolytically from the
native RAGE expressed on the cell surface [14,15].
In our population, we found a significant increase of esRAGE levels
after the weight loss due to lifestyle treatment. The effectiveness of
therapeutic lifestyle changes in improving or preventing the
components of the metabolic syndrome has already been
demonstrated in adults [16], but only few studies demonstrated that
weight reduction resulted in an improvement of the metabolic
syndrome and of the atherogenic risk-factor profile in children. A
positive association between HOMA-IR, waist circumference (WC),
lipid profile, and BMI was found [17], while the few studies evaluating
the impact of weight loss on serum markers of systemic inflammation
in obese children reported controversial results. In one study, the
prevalence of metabolic syndrome decreased in adolescents if they
followed a better overall Healthy Eating Index and if they trained more
physical activities [18].
Furthermore, in particular, only few previous studies evaluated the
impact of weight loss of markers of systemic inflammation levels in
obese children (Table 4).
Authors Molecules in study Intervention Age of patients (year) Number of
patients
Results
Gong l et al. IL-6 1 year of lifestyle modification 7-11 326 Reduction of IL-6
conc.






Nemet et al. IL-6 3 months dietary intervention and
exercise program
10.4 ± 1.96 21 No change in IL-6
Roberts et al. IL-6 2 week program of low-fat diet and daily
exercise program
13.1 ± 0.5 19 Reduction of IL-6
conc.
Rynders et al. IL-6 6 months of hypocaloric diet, exercise,
and metformin
14.3 ± 2.4 16 Reduction of IL-6
conc.
Izadpanah et al. IL-6 2 week residential lifestyle modification 13.0 ± 0.5 21 Reduction of IL-6
conc.
Roth et al. IL-6 1 year lifestyle modification 29 No change in IL-6
Garanty-Bogacka et al. IL-6 6-month hypocaloric diet and moderate
physical activity
14.2 ± 2.6 50 Reduction of IL-6
conc.
Martos-Moreno et al. IL-6 18 months of physical activity program
and reorganization of eating habits
8.92 ± 1.80 51 Reduction of IL-6
conc.
Amati et al. IL-6 6 month hypocaloric diet 8.9 ± 0.5 35 No change in IL-6
Balagopal et al. IL-6 6 month lifestyle modification adolescents 15 Reduction of IL-6
conc.
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Gallistl et al. IL-6 3 weeks hypocaloric diet and increase in
physical activity
11.9 ± 1.8 49 Reduction of IL-6
conc.
Table 4: Review of existing studies in pediatric population.
Among these studies, Gong et al. [19], Roberts et al. [20], Rynders et
al. [21], Izadpanah et al. [22], Garanty-Bogacka et al. [23], Martos
Moreno et al. [24], Balagopal et al. [25] and Gallistl et al. [26] showed
similar change in IL-6 levels after decrease of BMI. On the other side,
Nemet et al. [27], Roth et al. [28], and Amati et al. [29] found no
significant change. D’Adamo et al. [30] recently demonstrated a
significant increase of esRAGE in obese children after life style
intervention combined with Vitamin E supplementation.
In two studies [20,21], a medical treatment was added to the diet. In
five cases [19,21,24-26], the follow-up lasted only few weeks and it
comprises a program of intensive physical activity and hypocaloric diet
without including a gradual change in lifestyle intervention and eating
habits.
To our best knowledge, no data on the role of ET-1 in children after
weight loss is yet available, for these reasons our results are a new
developments compared to previous literature.
In childhood, these kinds of programs need the inclusion of a multi-
disciplinary team. Therefore, they are expensive and, thus, they could
be usually conducted for a short period. In addition, most of the
proven beneficial effects do not persist once the program is completed.
Only in three published studies [17,19,24], the patients were reported
to be follow for at least one year and the proposed programs was
similar to the one we conducted in our study attempting to modify
permanently lifestyle.
The main bias of our study is the small population sample reflecting
the complexity to collect longitudinal data over a long-term follow-up
period, especially among patients with severe obese that usually are not
so compliant to new lifestyle suggestions. Since our study focus
attention on IL-6, ET-1 and esRAGE, it could be expanded with
evaluation of other chronic inflammation parameters.
Conclusion
Our study demonstrated that weight loss by lifestyle modifications
can improve both low-grade inflammation status and insulin
resistance in obese children. These changes appear long-term and
persistent in children presenting a severe degree of obesity and
experiencing a 1 years-long lifestyle intervention that includes dietary
and behavioral treatment to achieve a gradual change in the eating
habits of the whole family and a reduction of sedentary lifestyles.
In conclusion, we suggest that weight-reduction programme is
necessary in pre-pubertal and pubertal obese children with abnormal
glycemic and lipid profile as a prevention of metabolic syndrome later
in life, since we demonstrated that a non-intensive long-term weight
management program may significantly improve the degree of obesity
together with glucose metabolism, abnormal lipid profile and some
cardiovascular risk factor in childhood.
Informed Consent
Written informed consent for data collection was obtained from all
subjects and parents at the moment of recruitment in the study and
before the first data collection.
Ethical Considerations
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experimentation.
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